Control Cohort CTRL COH

Sponsor

Hospices Civils de Lyon (Other)

Overall Status

Not yet recruiting

CT.gov ID

NCT05370079

Collaborator

(none)

350

Enrollment

Location

Arm

Anticipated Duration (Months)

5.8

Patients Per Site Per Month

Study Details

Study Description

Brief Summary

Autoimmune encephalitis (AE) and paraneoplastic neurological syndromes (PNS) are rare disease that could be difficult to diagnose. So it necessary to obtain numerous sample from different disease to develop more specific diagnosis kit It could be possible through the characterisation of new genetic biomarkers.

Condition or Disease	Intervention/Treatment	Phase
Parkinson's Disease; Amyotrophic Lateral Sclerosis; Glioblastoma; Cancer Without Neurological Disease; Rheumatoid Polyarthritis	Biological: Collection of biological sample (blood and/or CSF)	N/A

Study Design

Study Type:

Interventional

Anticipated Enrollment :

350 participants

Allocation:

N/A

Intervention Model:

Single Group Assignment

Masking:

None (Open Label)

Primary Purpose:

Diagnostic

Official Title:

Control Cohort CTRL COH

Anticipated Study Start Date :

Aug 1, 2022

Anticipated Primary Completion Date :

Aug 1, 2027

Anticipated Study Completion Date :

Aug 1, 2027

Arms and Interventions

Arm	Intervention/Treatment
Other: Control cohort Patient with following disease: Parkinson's disease, Amyotrophic lateral sclerosis, Glioblastoma, cancer without neurological disease (pulmonary cancer, breast cancer, ovarian cancer, melanoma, thymoma), rheumatoid arthritis.	Biological: Collection of biological sample (blood and/or CSF) Blood sample will be collected one time for each patient: 2 4ml of blood on dry tube 2 4ml of blood on EDTA tube If cerebrospinal fluid (CSF) has been drawn for diagnosis, remaining sample available will be stored in the control cohort (1 ml).

Arm

Intervention/Treatment

Other: Control cohort

Patient with following disease: Parkinson's disease, Amyotrophic lateral sclerosis, Glioblastoma, cancer without neurological disease (pulmonary cancer, breast cancer, ovarian cancer, melanoma, thymoma), rheumatoid arthritis.

Biological: Collection of biological sample (blood and/or CSF)

Blood sample will be collected one time for each patient: 2 *4ml of blood on dry tube 2 *4ml of blood on EDTA tube If cerebrospinal fluid (CSF) has been drawn for diagnosis, remaining sample available will be stored in the control cohort (1 ml).

Outcome Measures

Primary Outcome Measures

Samples (blood dry and EDTA tube and optional cerebro-spinal-fluid) [15 minutes]
Numbers of samples collected and patients included in the cohort

Secondary Outcome Measures

Description of genetic analysis [Data collecting: 3 years Data analysis: 2 years]
Number of new biomarkers (genetic) and specific HLA (human leucocyte antigen)

Eligibility Criteria

Criteria

Ages Eligible for Study:

18 Years and Older

Sexes Eligible for Study:

All

Accepts Healthy Volunteers:

Inclusion Criteria:

patient with consent
patient with following disease: Parkinson's disease, Amyotrophic lateral sclerosis, Glioblastoma, cancer without neurological disease (pulmonary cancer, breast cancer, ovarian cancer, melanoma, thymoma), rheumatoid arthritis.

Exclusion Criteria:

refusal consent
patient with neurological disorder compatible with paraneoplastic neurological syndrome or auto-immune encephalitis
patient under guardianship

Contacts and Locations

Locations

	Site	City	State	Country	Postal Code
1	Hospices Civils de Lyon	Bron		France	69500

Sponsors and Collaborators

Hospices Civils de Lyon

Investigators

Principal Investigator: Jerome Honnorat, Pr, Centre de référence des syndromes neurologiques paranéoplasiques et encéphalites auto-immunes, Lyon, France